Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective

References

• Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132–1138.
   PubMed Web of Science ®Google Scholar
• Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284–1293.
   PubMed Web of Science ®Google Scholar
• Avail Dermatology. Top 5 Most Common Skin Conditions. 2018. [cited 2021 Jun 10]. Available from: https://availdermatology.com/common-skin-conditions/.
   Google Scholar
• Williams HC, editor. Atopic dermatitis: the epidemiology, causes, and prevention of atopic eczema. Cambridge: Cambridge University Press; 2000.
   Google Scholar
• Vakharia PP, Chopra R, Sacotte R, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol. 2017;119(6):548–552. e3.
   PubMed Web of Science ®Google Scholar
• Cheng C-M, Hsu J-W, Huang K-L, et al. Risk of developing major depressive disorder and anxiety disorders among adolescents and adults with atopic dermatitis: a nationwide longitudinal study. J Affect Disord. 2015;178:60–65.
   PubMed Web of Science ®Google Scholar
• Love I, White K. Atopic dermatitis/atopic eczema: disease landscape & forecast. Decision Resources Group. 2020.
   Google Scholar
• Senra MS, Wollenberg A. Psychodermatological aspects of atopic dermatitis. Br J Dermatol. 2014;170(Suppl 1):38–43.
   PubMedGoogle Scholar
• Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340–347.
   PubMed Web of Science ®Google Scholar
• Ariëns LFM, van Nimwegen KJM, Shams M, et al. Economic burden of adult patients with moderate to severe atopic dermatitis indicated for systemic treatment. Acta Derm Venereol. 2019;99(9):762–768.
   PubMed Web of Science ®Google Scholar
• Frazier W, Bhardwaj N. Atopic dermatitis: diagnosis and treatment. Am Fam Physician. 2020;101(10):590–598.
   PubMedGoogle Scholar
• Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Dupilumab for treating moderate to severe atopic dermatitis: Technology appraisal guidance [TA534]. 2018. [cited 2021 Jun 10]. Available from: https://www.nice.org.uk/guidance/TA534.
   Google Scholar
• European Medicines Agency. Rinvoq: upadacitinib. 2021. [cited 2021 Dec 19]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq.
   Google Scholar
• Medicines and Healthcare products Regulatory Agency. SUMMARY OF PRODUCT CHARACTERISTICS. 2021. [cited 2021 Oct 23]. Available from: https://mhraproducts4853.blob.core.windows.net/docs/9890d20041d9d6b42d1d098c89bfe58333260ad7.
   Google Scholar
• National Institute for Health and Care Excellence. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]: In development [GID-TA10597]. 2021. [cited 2021 Jun 10]. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-ta10597.
   Google Scholar
• European Medicines Agency. Cibinqo: abrocitinib. 2021. [cited 2021 Dec 19]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cibinqo.
   Google Scholar
• National Institute for Health and Care Excellence. Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]: In development [GID-TA10596]. 2021. [cited 2021 Jun 28]. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-ta10596.
   Google Scholar
• Drummond MF, Sculpher M, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th edn. Oxford: Oxford University Press; 2015.
   Google Scholar
• Ling DI, Lynd LD, Harrison M, et al. Early cost-effectiveness modeling for better decisions in public research investment of personalized medicine technologies. J Comp Eff Res. 2019;8(1):7–19.
   PubMed Web of Science ®Google Scholar
• Nelson HD. Systematic reviews to answer health care questions. Philadelphia: Wolters Kluwer Health; 2014.
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Institute for clinical and economic review. Dupilumab and crisaborole for atopic dermatitis: effectiveness and value. 2017. [cited 2021 Jul 4]. Available from: https://icer.org/wp-content/uploads/2020/10/MWCEPAC_ATOPIC_EVIDENCE_REPORT_051217.pdf.
   Google Scholar
• National Institute for Health and Care Excellence. Baricitinib for treating moderate to severe atopic dermatitis: technology appraisal guidance [TA681]. 2021. [cited 2021 Jun 10]. Available from: https://www.nice.org.uk/guidance/ta681.
   Google Scholar
• Mauskopf J, Chirila C, Birt J, et al. Drug reimbursement recommendations by the national institute for health and clinical excellence: have they impacted the national health service budget? Health Policy. 2013;110(1):49–59.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE Mono-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–266.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–449.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877–884.
   PubMed Web of Science ®Google Scholar
• Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.
   PubMedGoogle Scholar
• Blauvelt A, M de B-W, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047–1055.
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. National life tables: UK. 2021. [cited 2021 May 6]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables.
   Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. 2013. [cited 2021 Jun 10]. Available from: https://www.nice.org.uk/process/pmg9/chapter/foreword.
   Google Scholar
• Curtis L, Burns A. Unit Costs of Health and Social Care 2019 | PSSRU. 2019. [cited 2021 Jun 6]. Available from: https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2019/.
   Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)-explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines good reporting practices task force. Value Health. 2013;16(2):231–250.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. BNF British National Formulary. 2021. [cited 2021 May 6]. Available from: https://bnf.nice.org.uk/
   Google Scholar
• National Health Service. National tariff payment system documents, annexes and supporting documents. 2020. [cited 2021 Jun 10]. Available from: https://www.england.nhs.uk/publication/national-tariff-payment-system-documents-annexes-and-supporting-documents/
   Google Scholar
• National Health Service. National cost collection for the NHS. 2019. [cited 2021 Jun 10]. Available from: https://www.england.nhs.uk/national-cost-collection/
   Google Scholar
• Institute for clinical and economic review. JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value. 2021. [cited 2021 Jul 4]. Available from: https://icer.org/wp-content/uploads/2020/12/ICER_Atopic-Dermatitis_Draft-Evidence-Report_051421.pdf
   Google Scholar
• Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Med Decis Making. 2012;32(5):733–743.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Lei D, Yousaf M, et al. What are the best endpoints for eczema area and severity index and scoring atopic dermatitis in clinical practice? A prospective observational study. Br J Dermatol. 2021;184(5):888–895.
   PubMed Web of Science ®Google Scholar